Physician profile
Danielle Grauer
NPI 1831593573
$959.00
in general payments reported to CMS, 2019-2025
12 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.01 · 2022: $211 · 2023: $297 · 2024: $72.16 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $263.61 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.79 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $150.70 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $89.87 | 2021-2025 | |
| Orphalan INC | $57.33 | 2024-2025 | Cuvrior |
| Alkermes, INC. | $37.12 | 2023 | Vivitrol |
| Galderma Laboratories, L.P. | $32.88 | 2025 | Dysport |
| Celgene Corporation | $28.94 | 2024 | Reblozyl |
| Melinta Therapeutics, LLC | $22.14 | 2023 | Vabomere, Orbactiv, Kimyrsa |
| Paratek Pharmaceuticals, INC. | $19.84 | 2022 | |
| Intercept Pharmaceuticals, INC. | $17.64 | 2025 | |
| Revance Therapeutics, INC. | $13.14 | 2024 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Grauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.